[Comment] Current status of cardiovascular risk factor control in antiphospholipid syndrome: where are we now?

The publication of the 2023 American College of Rheumatology and European Alliance of Associations for Rheumatology antiphospholipid syndrome (APS) classification criteria marks a substantial advancement in the disease's classification and evaluative framework.1 Departing from the 2006 Sapporo criteria2 that used a broad definition of thrombotic events, the updated criteria explicitly differentiate between arterial and venous thrombosis. Moreover, they place greater emphasis on the role of traditional cardiovascular risk factors in modulating thrombotic risk, moving beyond a sole focus on the prothrombotic effects of antiphospholipid antibodies.